Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 10/20 | 0.39 |
| ▸ | MTOR | P42345 | 9/20 | 0.39 |
| ▸ | PRKDC | P78527 | 2/20 | 0.35 |
| ▸ | TNF | P01375 | 1/20 | 0.31 |
| ▸ | LITAF | Q99732 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | ATR | Q13535 | 1/20 | 0.31 |
| ▸ | CCR5 | P51681 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30493857 | 1.00 | PIK3CA (0.39) | PIK3CAMTORPRKDCTNFLITAF | |
| SCHEMBL24469143 | 0.87 | PIK3CA (0.38) | PIK3CAMTORPRKDC | |
| SCHEMBL26083484 | 0.83 | ATM (0.37) | PIK3CAMTORPRKDCATM | |
| SCHEMBL29809584 | 0.83 | ATM (0.37) | PIK3CAMTORPRKDCATM | |
| SCHEMBL27214147 | 0.78 | ATM (0.32) | PIK3CAMTORPRKDCATMATR | |
| SCHEMBL24469144 | 0.74 | PIK3CA (0.35) | PIK3CAMTORPRKDCATMATR | |
| SCHEMBL30493923 | 0.73 | DPP4 (0.32) | PIK3CAPRKDC | |
| SCHEMBL24469190 | 0.72 | PIK3CA (0.36) | PIK3CAMTORPRKDCATMATR | |
| SCHEMBL30493704 | 0.71 | PIK3CA (0.30) | PIK3CAMTOR | |
| SCHEMBL30493781 | 0.71 | DPP4 (0.34) | PIK3CAMTORPRKDCATMATR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12187725-B2 | Tricyclic urea compounds as JAK2 V617F inhibitors | INCYTE CORPORATION (US) | 2025-01-07 | — | — | US | disclosed |
| US-20240150354-A1 | TRICYCLIC UREA COMPOUNDS AS JAK2 V617F INHIBITORS | INCYTE CORPORATION | 2024-05-09 | — | — | US | disclosed |
| EP-4175719-A1 | TRICYCLIC UREA COMPOUNDS AS JAK2 V617F INHIBITORS | Incyte Corporation (US) | 2023-05-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240150354-A1 | TRICYCLIC UREA COMPOUNDS AS JAK2 V617F INHIBITORS | JAK2, JAK1, JAK3 | PIK3CA 444/4885MTOR 196/4885PRKDC 74/4885 |
| US-12187725-B2 | Tricyclic urea compounds as JAK2 V617F inhibitors | JAK2, JAK1, JAK3 | PIK3CA 444/4885MTOR 196/4885PRKDC 74/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.